# Lithium chloride suppresses ferroptosis of induced pluripotent stem cells with ApoE4/E4 from a sporadic Alzheimer's disease patient

**Authors:** Ying Wang, Samuel Anchipolovsky, Piplu Bhuiyan, Luna Sato, Ge Liang, De-Maw Chuang, Huafeng Wei

PMC · DOI: 10.1016/j.neurot.2026.e00860 · Neurotherapeutics · 2026-02-26

## TL;DR

Lithium chloride helps protect brain cells from a type of cell death linked to Alzheimer's disease in cells with a specific genetic risk factor.

## Contribution

This study shows lithium chloride reverses ferroptosis in ApoE4/E4 iPSCs from a sporadic Alzheimer's patient.

## Key findings

- Lithium treatment improved cell viability and reversed ferroptosis markers in ApoE4/E4 iPSCs.
- Lithium normalized mitochondrial function and reduced ROS production in these cells.
- Lithium inhibited Ca2+ signaling by reducing InsP3R-1 protein expression.

## Abstract

Alzheimer's disease (AD), particularly its sporadic form (SAD, 95 % AD patients), is strongly associated with the apolipoprotein E4 (ApoE4) genotype and characterized by oxidative stress, iron dysregulation, and increased susceptibility to ferroptosis. Lithium, a well-established neuroprotective agent, has shown potential to mitigate several pathological mechanisms in AD, including ferroptosis. This study investigates the therapeutic potential of lithium chloride in human induced pluripotent stem cells (iPSCs) derived from a SAD patient with ApoE4/E4 genotype and compared effects with those of isogenic gene-edited ApoE3/E3 control. Lithium treatment significantly improved cell viability in ApoE4/E4 iPSCs. It also reversed key ferroptosis phenotypes, including elevated cytosolic Fe2+, increased expression of divalent metal transporter 1, reduced level of glutathione peroxidase 4, enhanced lipid peroxidation and excessive ROS production. Moreover, lithium (0.25 mM) normalized mitochondrial respiration and reduced proton leak, indicating preservation of mitochondrial function and protection against mitochondrial damage and cell death. Lithium also reduced the expression of type 1 InsP3 receptor (InsP3R-1) protein, a Ca2+ channel located on the endoplasmic reticulum (ER) membrane. Together, these findings highlight lithium's inhibition of ferroptosis through modulation of iron metabolism, antioxidant defenses and inhibition of disrupted Ca2+ signaling. Given the drug's demonstrated efficacy in reversing ApoE4-driven cellular vulnerabilities, lithium salt warrants further investigation for the treatment of AD.

## Linked entities

- **Genes:** APOE (apolipoprotein E) [NCBI Gene 348], GPX4 (glutathione peroxidase 4) [NCBI Gene 819427], ITPR1 (inositol 1,4,5-trisphosphate receptor type 1) [NCBI Gene 3708]
- **Proteins:** ITPR1 (inositol 1,4,5-trisphosphate receptor type 1)
- **Chemicals:** lithium chloride (PubChem CID 433294), Fe2+ (PubChem CID 23925)
- **Diseases:** Alzheimer's disease (MONDO:0004975)

## Full-text entities

- **Genes:** GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, ITPR1 (inositol 1,4,5-trisphosphate receptor type 1) [NCBI Gene 3708] {aka ACV, CLA4, INSP3R1, IP3R, IP3R1, PPP1R94}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}
- **Diseases:** SAD (MESH:D017825), AD (MESH:D000544), mitochondrial damage (MESH:D028361)
- **Chemicals:** Lithium chloride (MESH:D018021), lipid (MESH:D008055), Ca2+ (-), Lithium (MESH:D008094), iron (MESH:D007501)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12993404/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12993404/full.md

## References

54 references — full list in the complete paper: https://tomesphere.com/paper/PMC12993404/full.md

---
Source: https://tomesphere.com/paper/PMC12993404